Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Melanoma 6Neoplasms 2Uveal Melanoma 1Triple Negative Breast Neoplasms 1The Initial Aim of This Project is to Perform in Vitro Validation of Neoepitope Candidates Selected From Available Mutanome Data 1Skin Neoplasms 1Neoplasm Metastasis 1Healthy Adults 1Glioblastoma 1Eye Neoplasms 1Esophageal Neoplasms 1Diabetes Mellitus, Insulin-Dependent, 12 1Carcinoma 1Brain Neoplasms 1Biliary Tract Neoplasms 1

Interventions

Cisplatin 21pembrolizumab 16Gemcitabine 16Paclitaxel 15Radiotherapy 14Carboplatin 14Radiotherapy, Intensity-Modulated 13Cyclophosphamide 9Cetuximab 9Magnetic Resonance Spectroscopy 8Radiation 7padeliporfin 6Specimen Handling 6Oxaliplatin 6Fluorouracil 6Drug Therapy 6Docetaxel 6Capecitabine 6Bevacizumab 6anlotinib 5Nivolumab 5Irinotecan 5Erlotinib Hydrochloride 5Celecoxib 5poly ICLC 4fludarabine 4Standard of Care 4Sorafenib 4Leucovorin 4Ipilimumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Carcinoma × Peptides × Clear all
NCT06564623 2026-05-08

Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Recruiting
25 enrolled
Gastrointestinal

Diabetes Mellitus, Insulin-Dependent, 12, Biliary Tract Neoplasms, Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡